---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031140"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T21:26:53.906328+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29

## Summary
- Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.
- Cash and investments $468.3M; runway expected into H2 2026.
- On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.
- Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.
- CFO Jeff Trigilio to depart effective March 29, 2024, with transition support.

## SEC filing metadata
- accession: 0000950170-24-031140
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/cgem-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031140
- JSON: https://secwatch.observer/filing/0000950170-24-031140.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031140.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.